327 related articles for article (PubMed ID: 23052407)
1. A phase I study to assess the effect of food on the single dose bioavailability of the THC/CBD oromucosal spray.
Stott CG; White L; Wright S; Wilbraham D; Guy GW
Eur J Clin Pharmacol; 2013 Apr; 69(4):825-34. PubMed ID: 23052407
[TBL] [Abstract][Full Text] [Related]
2. A phase I study to assess the single and multiple dose pharmacokinetics of THC/CBD oromucosal spray.
Stott CG; White L; Wright S; Wilbraham D; Guy GW
Eur J Clin Pharmacol; 2013 May; 69(5):1135-47. PubMed ID: 23179176
[TBL] [Abstract][Full Text] [Related]
3. Piperine-pro-nanolipospheres as a novel oral delivery system of cannabinoids: Pharmacokinetic evaluation in healthy volunteers in comparison to buccal spray administration.
Cherniakov I; Izgelov D; Barasch D; Davidson E; Domb AJ; Hoffman A
J Control Release; 2017 Nov; 266():1-7. PubMed ID: 28890215
[TBL] [Abstract][Full Text] [Related]
4. PTL401, a New Formulation Based on Pro-Nano Dispersion Technology, Improves Oral Cannabinoids Bioavailability in Healthy Volunteers.
Atsmon J; Cherniakov I; Izgelov D; Hoffman A; Domb AJ; Deutsch L; Deutsch F; Heffetz D; Sacks H
J Pharm Sci; 2018 May; 107(5):1423-1429. PubMed ID: 29287930
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics of Sativex® in Dogs: Towards a Potential Cannabinoid-Based Therapy for Canine Disorders.
Fernández-Trapero M; Pérez-Díaz C; Espejo-Porras F; de Lago E; Fernández-Ruiz J
Biomolecules; 2020 Feb; 10(2):. PubMed ID: 32054131
[TBL] [Abstract][Full Text] [Related]
6. Tetrahydrocannabinol/Cannabidiol Oromucosal Spray in Patients With Multiple Sclerosis: A Pilot Study on the Plasma Concentration-Effect Relationship.
Contin M; Mancinelli L; Perrone A; Sabattini L; Mohamed S; Scandellari C; Foschi M; Vacchiano V; Lugaresi A; Riva R
Clin Neuropharmacol; 2018; 41(5):171-176. PubMed ID: 30024443
[TBL] [Abstract][Full Text] [Related]
7. Randomized, double-blind, placebo-controlled study about the effects of cannabidiol (CBD) on the pharmacokinetics of Delta9-tetrahydrocannabinol (THC) after oral application of THC verses standardized cannabis extract.
Nadulski T; Pragst F; Weinberg G; Roser P; Schnelle M; Fronk EM; Stadelmann AM
Ther Drug Monit; 2005 Dec; 27(6):799-810. PubMed ID: 16306858
[TBL] [Abstract][Full Text] [Related]
8. A phase 1, randomized, pharmacokinetic trial of the effect of different meal compositions, whole milk, and alcohol on cannabidiol exposure and safety in healthy subjects.
Crockett J; Critchley D; Tayo B; Berwaerts J; Morrison G
Epilepsia; 2020 Feb; 61(2):267-277. PubMed ID: 32012251
[TBL] [Abstract][Full Text] [Related]
9. Plasma cannabinoid pharmacokinetics following controlled oral delta9-tetrahydrocannabinol and oromucosal cannabis extract administration.
Karschner EL; Darwin WD; Goodwin RS; Wright S; Huestis MA
Clin Chem; 2011 Jan; 57(1):66-75. PubMed ID: 21078841
[TBL] [Abstract][Full Text] [Related]
10. A Phase I, open-label, randomized, crossover study in three parallel groups to evaluate the effect of Rifampicin, Ketoconazole, and Omeprazole on the pharmacokinetics of THC/CBD oromucosal spray in healthy volunteers.
Stott C; White L; Wright S; Wilbraham D; Guy G
Springerplus; 2013 Dec; 2(1):236. PubMed ID: 23750331
[TBL] [Abstract][Full Text] [Related]
11. Single-Dose Pharmacokinetics of Oral Cannabidiol Following Administration of PTL101: A New Formulation Based on Gelatin Matrix Pellets Technology.
Atsmon J; Heffetz D; Deutsch L; Deutsch F; Sacks H
Clin Pharmacol Drug Dev; 2018 Sep; 7(7):751-758. PubMed ID: 29125702
[TBL] [Abstract][Full Text] [Related]
12. A Phase I, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose, Multiple Dose, and Food Effect Trial of the Safety, Tolerability and Pharmacokinetics of Highly Purified Cannabidiol in Healthy Subjects.
Taylor L; Gidal B; Blakey G; Tayo B; Morrison G
CNS Drugs; 2018 Nov; 32(11):1053-1067. PubMed ID: 30374683
[TBL] [Abstract][Full Text] [Related]
13. Application device for THC:CBD oromucosal spray in the management of resistant spasticity: pre-production testing.
Montero-Escribano P; Vila Silván C
Expert Rev Med Devices; 2019 Sep; 16(9):835-840. PubMed ID: 31393179
[No Abstract] [Full Text] [Related]
14. The effect of Pro NanoLipospheres (PNL) formulation containing natural absorption enhancers on the oral bioavailability of delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD) in a rat model.
Cherniakov I; Izgelov D; Domb AJ; Hoffman A
Eur J Pharm Sci; 2017 Nov; 109():21-30. PubMed ID: 28736128
[TBL] [Abstract][Full Text] [Related]
15. Examining the Systemic Bioavailability of Cannabidiol and Tetrahydrocannabinol from a Novel Transdermal Delivery System in Healthy Adults: A Single-Arm, Open-Label, Exploratory Study.
Varadi G; Zhu Z; Crowley HD; Moulin M; Dey R; Lewis ED; Evans M
Adv Ther; 2023 Jan; 40(1):282-293. PubMed ID: 36308640
[TBL] [Abstract][Full Text] [Related]
16. Effect of tetrahydrocannabinol:cannabidiol oromucosal spray on activities of daily living in multiple sclerosis patients with resistant spasticity: a retrospective, observational study.
Mallada Frechín J
Neurodegener Dis Manag; 2018 Jun; 8(3):151-159. PubMed ID: 29851356
[TBL] [Abstract][Full Text] [Related]
17. Food effect on pharmacokinetics of cannabidiol oral capsules in adult patients with refractory epilepsy.
Birnbaum AK; Karanam A; Marino SE; Barkley CM; Remmel RP; Roslawski M; Gramling-Aden M; Leppik IE
Epilepsia; 2019 Aug; 60(8):1586-1592. PubMed ID: 31247132
[TBL] [Abstract][Full Text] [Related]
18. Simultaneous and sensitive analysis of THC, 11-OH-THC, THC-COOH, CBD, and CBN by GC-MS in plasma after oral application of small doses of THC and cannabis extract.
Nadulski T; Sporkert F; Schnelle M; Stadelmann AM; Roser P; Schefter T; Pragst F
J Anal Toxicol; 2005; 29(8):782-9. PubMed ID: 16356335
[TBL] [Abstract][Full Text] [Related]
19. A double-blind, randomized, placebo-controlled, parallel-group study of THC/CBD oromucosal spray in combination with the existing treatment regimen, in the relief of central neuropathic pain in patients with multiple sclerosis.
Langford RM; Mares J; Novotna A; Vachova M; Novakova I; Notcutt W; Ratcliffe S
J Neurol; 2013 Apr; 260(4):984-97. PubMed ID: 23180178
[TBL] [Abstract][Full Text] [Related]
20. Long-Term Data of Efficacy, Safety, and Tolerability in a Real-Life Setting of THC/CBD Oromucosal Spray-Treated Multiple Sclerosis Patients.
Paolicelli D; Direnzo V; Manni A; D'Onghia M; Tortorella C; Zoccolella S; Di Lecce V; Iaffaldano A; Trojano M
J Clin Pharmacol; 2016 Jul; 56(7):845-51. PubMed ID: 26608223
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]